<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695159</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012018-005</org_study_id>
    <nct_id>NCT03695159</nct_id>
  </id_info>
  <brief_title>The Perioperative Management of Anti-thrombotic Drug Registry</brief_title>
  <acronym>CNCS</acronym>
  <official_title>The Perioperative Management of Anti-thrombotic Drug Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate contemporary antiplatelet therapy management of&#xD;
      patients referred for non-cardiac and cardiac surgical procedures while on chronic therapy&#xD;
      with antiplatelet and/or anticoagulant drugs. These medications are routinely prescribed to&#xD;
      patients following percutaneous coronary interventions (PCI), known diagnosis of atrial&#xD;
      fibrillation, prosthetic heart valves, transcatheter aortic valve procedures, pulmonary&#xD;
      embolism, deep vein thrombosis, peripheral artery revascularization procedures etc. This is a&#xD;
      highly relevant and understudied clinical area with no randomized clinical trials or&#xD;
      large-scale prospective evidence, except for bridging data with unfractionated heparin (UFH).&#xD;
      Most recommendations and guidelines are based on consensus expert opinion. While post-PCI&#xD;
      patients, especially those treated with coronary stents are placed on dual antiplatelet&#xD;
      agents such as aspirin and P2Y12 blocking agents, performing surgery while on these agents&#xD;
      increase the risk of hemorrhagic complications, discontinuation or interruption of dual&#xD;
      antiplatelet therapy (DAPT) has been associated with adverse ischemic outcomes secondary to&#xD;
      myocardial infarction (MI) and stent thrombosis (ST). Moreover, there is only no clear&#xD;
      consensus regarding continuation of aspirin perioperatively in these patients. As in the case&#xD;
      of PCI, similar arguments for juxtaposed risks (thrombosis vs. bleeding) can be made for a&#xD;
      myriad of clinical situations where chronic (≥45 days) use antiplatelet and anticoagulant&#xD;
      medication (together referred to as antithrombotic drugs) are indicated. In addition, there&#xD;
      are many procedures and surgeries with different bleeding and ischemic risks that cannot be&#xD;
      studies through dedicated randomized studies and a registry collection of such information&#xD;
      could provide valuable guidance to providers and patients worldwide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Clinical Outcomes (Net Adverse Cardiovascular events (%))</measure>
    <time_frame>time of study reporting initiation (14 days prior to CNCS) to end of study (30 days post-CNCS).</time_frame>
    <description>A composite of Death, Non-Fatal MI, Ischemic Stroke, Need for Urgent Coronary Revascularization, and Bleeding (defined by Bleeding Associated Research Consortium- BARC)</description>
  </primary_outcome>
  <enrollment type="Actual">288</enrollment>
  <condition>Surgery</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on chronic antiplatelet and anticoagulant therapies and undergo a cardiac and&#xD;
        non-cardiac surgeries and procedures (CNCS)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment with antiplatelet and/or anticoagulant medications for ≥45 days prior to the&#xD;
             date of NCS.&#xD;
&#xD;
          -  Patients with planned, urgent or emergent cardiac or non-cardiac surgery or procedure&#xD;
             (CNCS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subhash Banerjee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Texas VA Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15(5):625-51. doi: 10.1093/europace/eut083.</citation>
    <PMID>23625942</PMID>
  </reference>
  <reference>
    <citation>Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014 Jul 21;35(28):1888-96. doi: 10.1093/eurheartj/eht557. Epub 2014 Jan 6.</citation>
    <PMID>24394381</PMID>
  </reference>
  <reference>
    <citation>Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.</citation>
    <PMID>26095867</PMID>
  </reference>
  <reference>
    <citation>Tsimikas S. Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. J Am Coll Cardiol. 2006 May 16;47(10):2112-5. Epub 2006 Apr 4.</citation>
    <PMID>16697332</PMID>
  </reference>
  <reference>
    <citation>Cruden NL, Harding SA, Flapan AD, Graham C, Wild SH, Slack R, Pell JP, Newby DE; Scottish Coronary Revascularisation Register Steering Committee. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv. 2010 Jun 1;3(3):236-42. doi: 10.1161/CIRCINTERVENTIONS.109.934703. Epub 2010 May 4.</citation>
    <PMID>20442357</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Subhash Banerjee</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>anti-thrombotic drugs</keyword>
  <keyword>cardiac intervention</keyword>
  <keyword>Non-cardiac intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

